In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
暂无分享,去创建一个
[1] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[2] D. Huntsman,et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. , 2010, Gynecologic oncology.
[3] V. L. Greenberg,et al. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. , 2010, Gynecologic oncology.
[4] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[5] Michael Bots,et al. Rational Combinations Using HDAC Inhibitors , 2009, Clinical Cancer Research.
[6] A. V. von Bueren,et al. Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities , 2009, Anti-cancer drugs.
[7] M. Lübbert,et al. Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes , 2009, Clinical Cancer Research.
[8] S. Modesitt,et al. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.
[9] Anil K Sood,et al. Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Kohno,et al. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs , 2008, Cancer science.
[11] V. Fantin,et al. Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications , 2007, Clinical Cancer Research.
[12] V. L. Greenberg,et al. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. , 2007, Gynecologic oncology.
[13] Shi-Wen Jiang,et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells , 2006, Molecular Cancer Therapeutics.
[14] R. Ohlinger,et al. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients , 2006, BMC Cancer.
[15] P. Bader,et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. , 2006, International journal of oncology.
[16] Y. Bang,et al. Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.
[17] J. Issa,et al. Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents , 2005, Cancer investigation.
[18] Nishan H Chobanian,et al. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. , 2004, Anticancer research.
[19] J. Arts,et al. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. , 2003, Current medicinal chemistry.
[20] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[21] Ricky W. Johnstone,et al. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.
[22] Vigushin Dm,et al. Histone deacetylase inhibitors in cancer treatment. , 2002 .
[23] D. Vigushin,et al. Histone deacetylase inhibitors in cancer treatment. , 2002, Anti-cancer drugs.
[24] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[25] V. Richon,et al. Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.
[26] P. Marks,et al. Inhibitors of histone deacetylase are potentially effective anticancer agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] P. Marks,et al. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.
[28] M. Piccart,et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.
[29] J. Workman,et al. Alteration of nucleosome structure as a mechanism of transcriptional regulation. , 1998, Annual review of biochemistry.
[30] E. Partridge,et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). , 1996, Seminars in oncology.